« Previous  |  Next »

ORIGINAL ARTICLE: Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-{alpha}-1,3-Galactose

Background Cetuximab, a chimeric mouse–human IgG1 monoclonal antibody against the epidermal growth factor receptor, is approved for use in colorectal cancer and squamous-cell carcinoma of the head and neck. A high prevalence of hypersensitivity ...

From CHUNG, C. H., MIRAKHUR, B., CHAN, E., LE, Q.-T., BERLIN, J., MORSE, M., MURPHY, B. A., SATINOVER, S. M., HOSEN, J., MAURO, D., SLEBOS, R. J., ZHOU, Q., GOLD, D., HATLEY, T., HICKLIN, D. J., PLATTS-MILLS, T. A.E., New England Journal of Medicine -- Recent Issues,  12 Mar 2008

Related Topics: Bristol-Myers Squibb,  Stanford University,  Harvard University

« Previous  |  Next »

Who is This?

Help us add to our database, by linking this writer their entry in Wikipedia or Source Watch, or by suggesting that we remove it from our index.

Suggest an Entry